Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HL068 vs Candesartan + Amlodipine in Healthy Volunteers
NCT02988362Phase 1Completed
- Sponsor
- HanAll Biopharma
- Start
- Dec 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of candesartan + amlodipine in hypertension (HTN) (2 arms), sponsored by HanAll Biopharma. Primary endpoints: Area Under the Curve to the last measurable concentration up to 72 hours and Maximum Plasma Concentration up to 72 hours. Started Dec 2016; status: completed.
02
Drugs
candesartan + amlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02988362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02988362.